Holen Sie sich die Stockscreener-App
1.205
0.00%
0.005
Schlusskurs vom Vortag:
$1.20
Offen:
$1.19
24-Stunden-Volumen:
622.48K
Relative Volume:
1.09
Marktkapitalisierung:
$149.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-4.82
EPS:
-0.25
Netto-Cashflow:
$-19.57M
1W Leistung:
-12.41%
1M Leistung:
-17.24%
6M Leistung:
-26.38%
1J Leistung:
+55.64%
1-Tages-Spanne:
$1.17
$1.22
1-Wochen-Bereich:
$1.17
$1.40
52-Wochen-Spanne:
$0.70
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Vergleichen Sie ATOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ATOS | 1.20 | 149.07M | 0 | -26.91M | -19.57M | -0.25 |
| VRTX | 449.14 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.83 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.39 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.01 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.99 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - The Manila Times
Atossa Therapeutics to Present New Cancer Treatment Research at AACR Conference | ATOS Stock News - StockTitan
Atossa Therapeutics announces five abstracts on Z-endoxifen - TipRanks
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - The Manila Times
Atossa's Endoxifen Breast Cancer Drug Data to Be Showcased at Major SABCS Conference | ATOS Stock News - StockTitan
ATOS FY2024 EPS Estimate Increased by Cantor Fitzgerald - MarketBeat
What is HC Wainwright's Estimate for ATOS FY2026 Earnings? - MarketBeat
Atossa Genetics stock target lifted, retains buy on positive study results - Investing.com UK
Atossa Therapeutics: Q3 2024 Financial Results and Updates - TipRanks
Atossa Therapeutics Inc (ATOS) Quarterly 10-Q Report - Quartzy
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Simply Wall St
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to “Sell” Rating by StockNews.com - Defense World
Atossa's Endoxifen Shows 26.5% Breast Density Reduction in Phase 2 Trial; Reports $74.8M Cash | ATOS Stock News - StockTitan
Atossa Therapeutics (NASDAQ:ATOS) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go - Seeking Alpha
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
Atossa Genetics shares hold Buy rating on positive trial results By Investing.com - Investing.com Canada
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development - The Manila Times
Atossa Therapeutics Strengthens Leadership Team with Key Clinical Development Executive | ATOS Stock News - StockTitan
Vanguard Group Inc's Strategic Acquisition of Atossa Therapeutics Inc Shares - GuruFocus.com
Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: - The Manila Times
Atossa Therapeutics (NASDAQ:ATOS) Receives “Buy” Rating from HC Wainwright - Defense World
Atossa Therapeutics' (ATOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
ATOSAtossa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - ForexTV.com
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer - The Manila Times
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s - The Bakersfield Californian
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (NASDAQ:ATOS) Upgraded to "Hold" at StockNews.com - MarketBeat
Atossa Therapeutics (NASDAQ:ATOS) Shares Cross Above 200 Day Moving AverageHere's Why - MarketBeat
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer - The Manila Times
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Atossa Therapeutics To Present At The 2024 Maxim Healthcare Virtual Summit - Barchart
Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Atossa Therapeutics Inc [ATOS] Investment Guide: What You Need to Know - Knox Daily
Is Atossa Therapeutics Inc (ATOS) worth investing in despite its overvalued state? - US Post News
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum - The Manila Times
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for - The Bakersfield Californian
Rhumbline Advisers Makes New $161,000 Investment in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Was Atossa Therapeutics Inc (ATOS)’s session last reading good? - US Post News
Bank of New York Mellon Corp Buys 399,041 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - Defense World
What Has Been Going On With Atossa Therapeutics Inc (NASDAQ: ATOS) - Stocks Register
Atossa Therapeutics Inc (ATOS) can make a big difference with a little luck - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.41 - MarketBeat
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is the investor’s view on Atossa Therapeutics Inc (ATOS)? - US Post News
Potential Price Increase for Atossa Therapeutics Inc (ATOS) After Recent Insider Activity - Knox Daily
Ratios Reveal: Breaking Down Atossa Therapeutics Inc (ATOS)’s Financial Health - The Dwinnex
Atossa Therapeutics Inc: Weathering Stock Market Storms with 182.35M Market Cap - The InvestChronicle
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):